Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ho-Sup Lee

Showing results (121-130 of 137) with videos related to

Pageof 14
Sort By:
International Journal of Hematology|September 15, 2010
Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma studySung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
International Journal of Hematology|September 5, 2020
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasoneHo Sup Lee, Kihyun Kim, Je-Jung Lee, et al.
Annals of Hematology|December 25, 2019
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)Jae-Cheol Jo, Ho Sup Lee, Kihyun Kim, et al.
Blood Cancer Journal|June 26, 2023
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantationDong Won Baek, Joon Ho Moon, Jae Hoon Lee, et al.
Frontiers in Oncology|September 7, 2023
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantationSeok Jin Kim, Jae-Cheol Jo, Dok Hyun Yoon, et al.
Blood Research|June 9, 2022
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in KoreaSeo-Yeon Ahn, Sang Kyun Son, Gyu Hyung Lee, et al.
Oncotarget|December 2, 2017
Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphomaJunshik Hong, Seok Jin Kim, Myung Hee Chang, et al.
Cancer Research and Treatment|April 25, 2022
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean CohortsJun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, et al.
Cancer Research and Treatment|January 6, 2022
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort StudySeong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, et al.
Haematologica|June 6, 2024
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 studyJi Hyun Lee, Jimin Choi, Chang-Ki Min, et al.
Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
International Journal of Hematology|September 15, 2010
Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma studySung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
International Journal of Hematology|September 5, 2020
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasoneHo Sup Lee, Kihyun Kim, Je-Jung Lee, et al.
Annals of Hematology|December 25, 2019
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)Jae-Cheol Jo, Ho Sup Lee, Kihyun Kim, et al.
Blood Cancer Journal|June 26, 2023
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantationDong Won Baek, Joon Ho Moon, Jae Hoon Lee, et al.
Frontiers in Oncology|September 7, 2023
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantationSeok Jin Kim, Jae-Cheol Jo, Dok Hyun Yoon, et al.
Blood Research|June 9, 2022
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in KoreaSeo-Yeon Ahn, Sang Kyun Son, Gyu Hyung Lee, et al.
Oncotarget|December 2, 2017
Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphomaJunshik Hong, Seok Jin Kim, Myung Hee Chang, et al.
Cancer Research and Treatment|April 25, 2022
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean CohortsJun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, et al.
Cancer Research and Treatment|January 6, 2022
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort StudySeong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, et al.
Haematologica|June 6, 2024
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 studyJi Hyun Lee, Jimin Choi, Chang-Ki Min, et al.
Pageof 14